CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

DE30: Beauty/luxury sector under pressure, Nordea keeps banking market sentiment!

12:59 17 July 2023
  • DE30 descends into 16,000-point region 

  • Beauty/luxury sector under pressure from China and Compagnie Financière Richemont results

  • Nordea's results keep banks afloat 

  • Successful testing of Argenx's innovative drug lifts its shares 28% higher

The mood in the markets during this week's first trading session is relatively negative. Europe is seeing fairly strong declines, above all in France, where the CAC 40 is losing more than 1% due to sizable declines in luxury goods and cosmetics companies. Sentiment was pressured today by data from China, which came in below expectations, which, combined with a weak sales reading from Compagnie Financière Richemont in the US, spoiled sentiment in the beauty/luxury sector.

Start investing today or test a free demo

Open account Try demo Download mobile app Download mobile app

The mood in Europe during Monday's trading session is relatively negative. At the moment, the worst performers are the shares of fashion companies, which are losing on the wave of weak macro data from China and the worse-than-expected US sales results of Compagnie Financière Richemont (CFR.CH). Source: xStation 5

German DE30 futures are losing nearly 0.32% during today's session and are slipping to support levels around 16,000 points. Source: xStation 5

News:

The theme of the day during today's session is fashion companies, whose shares are losing sharply on the back of weak data from China and reported lower sales in the US by Compagnie Financière Richemont (CFR.CH), which owns the Cartier brand, among others. 

Current quotations of selected fashion/luxury companies. Source: xStation 5

  • Chinese economic indicators showed growth in industrial production and retail sales below forecasts, while unemployment remained stable. China's Bureau of Statistics acknowledged that domestic economic conditions are improving, but cited complex global political and economic factors as challenges.

  • China's year-on-year (y/y) industrial production growth was 4.4%, higher than the 2.5% forecast and the 3.5% previously forecast.

  • China's unemployment rate remained at 5.2%, in line with the forecast and the previous rate.

  • China's year-on-year GDP growth was 6.3%, less than the 7.1% forecast but higher than the previous rate of 4.5%.

  • China's year-on-year retail sales growth was 3.1%, slightly below the forecast of 3.3% and well below the previous rate of 12.7%.

It is worth remembering that for all fashion companies, the Chinese market is one of the key markets. 

Interestingly, however, the mood around Richemont was spoiled today by weak sales data from the US, which may signal that the conjuncture for the industry is also being challenged in the West. 

Richemont's Q1 sales rose 14% to €5.32bn ($5.97bn), but organic growth of 19% was below expectations (20%) due to weak performance in the Americas (-4%).

Source: xStation 5

Nordea (NDA.FI), the largest bank in Scandinavia, reported a slightly higher than expected increase in operating profit in the second quarter, as rising interest rates outweighed negative foreign exchange differences. 

The bank's operating profit rose year-on-year by 26% to €1.72 billion, against an average forecast of €1.70 billion in a survey by Refinitiv. 

On the back of the surge, European banks managed to limit broad-market declines. 

Belgian drugmaker Argenx (ARGX.BE) today communicated that its treatment with an antibody called Vyvgart has significantly delayed the progression of an autoimmune nerve disorder that causes loss of sensation and muscle strength in the arms and legs. The positive result - a 61% reduction in the risk of relapse compared to placebo. The company's shares are gaining nearly 28% in today's session. 

The company's shares are climbing to their new historic highs today. Source: xStation 5

The largest percentage changes in individual companies of the DAX index. Source: Bloomberg

News from individual companies in the DAX index. Source: Bloomberg

 

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Back
Xtb logo

Join over 1 Million investors from around the world

We use cookies

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

This group contains cookies that are necessary for our websites to work. They take part in functionalities like language preferences, traffic distribution or keeping user session. They cannot be disabled.

Cookie name
Description
SERVERID
userBranchSymbol cc 2 March 2024
adobe_unique_id cc 1 March 2025
test_cookie cc 1 March 2024
SESSID cc 9 September 2022
__hssc cc 1 March 2024
__cf_bm cc 1 March 2024
intercom-id-iojaybix cc 26 November 2024
intercom-session-iojaybix cc 8 March 2024

We use tools that let us analyze the usage of our page. Such data lets us improve the user experience of our web service.

Cookie name
Description
_gid cc 9 September 2022
_gat_UA-22576382-1 cc 8 September 2022
_gat_UA-121192761-1 cc 8 September 2022
_ga_CBPL72L2EC cc 1 March 2026
_ga cc 1 March 2026
AnalyticsSyncHistory cc 8 October 2022
af_id cc 31 March 2025
afUserId cc 1 March 2026
af_id cc 1 March 2026
AF_SYNC cc 8 March 2024
__hstc cc 28 August 2024
__hssrc

This group of cookies is used to show you ads of topics that you are interested in. It also lets us monitor our marketing activities, it helps to measure the performance of our ads.

Cookie name
Description
MUID cc 26 March 2025
_omappvp cc 11 February 2035
_omappvs cc 1 March 2024
_uetsid cc 2 March 2024
_uetvid cc 26 March 2025
_fbp cc 30 May 2024
fr cc 7 December 2022
muc_ads cc 7 September 2024
lang
_ttp cc 26 March 2025
_tt_enable_cookie cc 26 March 2025
_ttp cc 26 March 2025
hubspotutk cc 28 August 2024

Cookies from this group store your preferences you gave while using the site, so that they will already be here when you visit the page after some time.

Cookie name
Description
personalization_id cc 7 September 2024
UserMatchHistory cc 8 October 2022
bcookie cc 8 September 2023
lidc cc 9 September 2022
lang
bscookie cc 8 September 2023
li_gc cc 7 March 2023

This page uses cookies. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. For more information see our Privacy Policy You can manage cookies by clicking "Settings". If you agree to our use of cookies, click "Accept all".

Change region and language
Country of residence
Language